Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ · Healthcare
Alnylam Pharmaceuticals Inc Operating Income 2008–2025
Alnylam Pharmaceuticals Inc annual/quarterly operating income history and growth rate from 2008 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Alnylam Pharmaceuticals Inc operating income for the quarter ending September 30, 2025 was 368.0 M, a 578.49% decrease year-over-year.
- Alnylam Pharmaceuticals Inc operating income for the twelve months ending September 30, 2025 was 293.0 M, a 2816.32% decrease year-over-year.
- Alnylam Pharmaceuticals Inc annual operating income for 2025 was 501.6 M, a 383.56% decrease from 2024.
- Alnylam Pharmaceuticals Inc annual operating income for 2024 was -176.9 M, a 37.31% decrease from 2023.
- Alnylam Pharmaceuticals Inc annual operating income for 2023 was -282.2 M, a 64.06% decrease from 2022.
- Alnylam Pharmaceuticals Inc annual operating income for 2022 was -785.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Alnylam Pharmaceuticals Inc Operating Income — FAQ
Alnylam Pharmaceuticals Inc (ALNY) operating income over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
What is Alnylam Pharmaceuticals Inc's operating income?
Alnylam Pharmaceuticals Inc (ALNY) reported operating income of $502M for fiscal 2025.
Where can I see ALNY's operating income history?
The chart and table above show Alnylam Pharmaceuticals Inc's operating income by year and by quarter, including the growth rate.